-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Phase I clinical trials will be a randomized, double-blind, placebo-controlled study designed to assess the safety, pharmacodynamics, and pharmacodynamics of ABBV-47D11 in a single dose climb in COVID-19 adult hospitalized populations.
the trial will be tested in three dose groups on 24 patients at multiple research bases around the world, with the main endpoints assessing drug-related adverse events and setting up multiple secondary endpoints.
in preclinical studies, the antibody showed the potential to block SARS-CoV-2 and SARS-CoV-1 infections.
under the equity introduction agreement, AbbVie will be responsible for the clinical study of ABBV-47D11 and, if successful, for the global production and commercialization process.
at the same time, AbbVie will pay a one-time equity transfer fee and a phased fee for the development, regulation and sale of the antibody's equity to Platinum Pharmaceuticals and the University of Ulysses, as well as a tiered royalty on net commercial sales.
university medical center in Therasmus was involved in the basic science section of the study and did not participate in the signing of the authorization agreement.
remaining terms have not been disclosed.
note: There are deletions in the original text